CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is the most commonly prescribed initial therapy for PTCL, despite results showing that the majority of PTCL patients have an inferior outcome compared with their B cell counterparts receiving CHOP, with the exception of ALK-positive ALCL. This evidence concerns the gene ALK and anaplastic large cell lymphoma.